|  Publicar respuesta

I didn't go to university http://tubearchive.online efukt Aegis Capital Corp began coverage of the biotechnologycompany with a "buy" rating, saying preliminary data of itsbladder and lung cancer study could be out later in the year andpositive outcomes could make it a prime acquisition candidate.

Añadir comentario